Company Overview and News


Add NRT
to your dashboard

Headline News

Novogen signs agreement to facilitate brain cancer clinical trials in China

2017-11-13 proactiveinvestors.com.au
Novogen Limited (ASX:NRT) has entered into an agreement with Cedrus Investments Ltd for advisory services to establish a corporate structure focused on the Greater China region.

Novogen Board Directors Take 50% Pay Cut to Conserve Cash

2017-08-14 biospace
SYDNEY, Aug. 14, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

Novogen: Access latest PPT from Proactive's CEO Sessions

2017-04-13 proactiveinvestors.com.au
Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April. Novogen is an emerging oncology drug developer with two clinical-stage programs.

Novogen on track to commence phase II trial of brain cancer therapy

2017-04-10 proactiveinvestors.com.au
Novogen (ASX:NRT, NASDAQ:NVGN) is on track to commence the phase II human trial of its GDC-0084 brain cancer therapy in calendar year 2017.

C-Suite Shakeup: Novogen CEO North America, CSO and CFO Exit in Reorg

2017-03-10 biospace
- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC position Novogen for success in these activities

Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

2017-03-10 prnewswire
- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC position Novogen for success in these activities

Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

2017-03-06 prnewswire
Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS).

Novogen awarded A$3M grant for novel cancer therapy

2017-02-09 proactiveinvestors.com.au
Novogen (ASX:NRT, NASDAQ:NVGN) has been awarded a grant of up to A$3 million by the Australian Federal Government for a novel cancer drug discovery program.

Noxopharm Ltd targets cancer cells that survive radiotherapy

2016-08-22 proactiveinvestors.com.au
Newly listed Noxopharm Ltd (ASX:NOX) has initiated a major research program testing the ability of its experimental drug NOX66 to promote the anti-cancer effects of radiotherapy. The ability of the active ingredient of NOX66, idronoxil, to cancel cancer drug resistance mechanisms is believed to have the potential to increase the effectiveness of radiotherapy and chemotherapy. The program will be based around pilot clinical studies in several countries including Australia, involving relatively small numbers of patients with specific cancer types. (0-1)

Novogen provides Cantrixil update

2016-05-02 asx.com.au

Corporate Governance Statement

2016-04-26 asx.com.au